Bharat Book Bureau

Choices in Cord Blood Banking Factors Influencing Parental Decision Making

Cord blood banking is increasingly being used to improve and save lives. Stem cells derived from umbilical blood have been used in more than 14,000 transplants worldwide to treat a wide range of blood diseases, genetic and metabolic disorders, immunodeficiencies and various forms of cancer. However, many expectant parents still do not fully understand the significance of cord blood storage. A study published in the Journal of Reproductive Medicine shows that a third of expectant parents are unaware of the option to preserve cord blood. Of the two-thirds who have some knowledge, 74% describe themselves as ¡§minimally informed.¨

Part 1 of this market report used proprietary data-derivation techniques to analyze conditions of the cord blood banking industry. Part 2 of this report used an end-user survey of expectant parents to identify and analyze the factors involved in the decision to privately store, publicly donate, or discard cord blood at birth. More than 1,200 expectation parents throughout the U.S., as well as Canada, Mexico, Europe, Asia, South/Central America, Australia and other regions answered the detailed survey between November 2008 and January 2009.
The report includes:

Sources through which expectant parents learn of cord blood banking
Rates of parental awareness of cord blood banking by gender, household income, geographic location, education, birth order, and other critical factors
Reasons parents cite as driving the decision to store cord blood
Factors influencing the decision for private vs. public storage of cord blood
Price sensitivity and quality expectations
Comparative analysis of quality variables among cord blood banks and parent perceptions of them
Parental responsiveness to health statistics
Differences in perspective based on global region, as well as differences due to location (city vs. suburban vs. rural)
Critical trends in cord blood banking and the factors influencing them
Competitive analysis of the Cord Blood Banking Industry, including:

U.S. Public Cord Blood Banks
U.S. Private Cord Blood Banks
International Public Cord Blood Banks
International Private Cord Blood Banks
Population Profiling: Characteristics of those highly/moderately/least likely to purchase cord blood banking services

Methods to effectively communicate with your target audience: Expectant Parents
And much more…

Table of Contents:

PART 1: CORD BLOOD BANKING, INDUSTRY OVERVIEW
I. Abstract
II. Cord Blood Stem Cells

A. Fetal Cord Blood Characteristics

B. Existing Treatments

C. Future Applications

III. Cord Blood Banking Industry

A. History

B. Private vs. Public Cord Blood Banks

1. U.S. Public Banks

a. Overview

b. Number of Public Banks

c. Geographic  Distribution

2. U.S. Private Banks

a. Overview

b. Number of U.S. Private Banks

c. Geographic  Distribution

3. Free Programs for U.S. Families with Medical Need

4. International Banks

a. Overview

b. Number Private Cord Blood Banks by International Region

IV. Market Characterization

A. List of U.S.  Private Cord Blood Banks

B. List of U.S. Public Cord Blood Banks

C. U.S. Mail-In Donation Cord Blood Banks

D. Breakdown of Canadian Cord Blood Banks – Public vs. Private / AABB Accredited vs. Non-Accredited

E. International Cord Blood Banks

1. Mexican Cord Blood Banks

a. Private Banks

b. Public Banking System

2. South/Central American Cord Blood Banks

a. Private Banks

b. Public Banking System

3. United Kingdom Cord Blood Banks

a. Private Banks

b. Public Banking System

4. European Cord Blood Banks

a. Private Banks

b. Public Banking System

5. Middle Eastern Cord Blood Banks

a. Private Banks

b. Public Banking System

6. Indian Cord Blood Banks

a. Private Banks

b. Public Banking System

7. Asian Cord Blood Banks

a. Private Banks

b. Public Banking System

8. Australian / New Zealand Cord Blood Banks

a. Private Australian and New Zealand Cord Blood Banks

b. Public Cord Blood Banks by Australian State

i. New South Wales

ii. Victoria

iii. Queensland

iv. Western Austalia, South Australia, & Tasmania

9. African Cord Blood Banks

a. Private Banks

b. Public Banking System

F. List of International Public Cord Blood Banks (Alphabetical by Country)

G. Worldwide List of AABB Accredited Cord Blood Facilities

V. United States Cord Blood Banking Legislation

A. U.S. State

B. U.S. Federal

1. Institute of Medicine Recommendations Study

a. Overview

b. Key Recommendations

c. IOM Study Shapes National Public Health Policy

2. Presidential Executive Order Expanding Approved Stem Cell Lines in Ethically Responsible Ways

a. Background

b. The Order

3. The Stem Cell Therapeutic and Research Act of 2005

a. Background

b. Current Status of the Act

VI. International Analysis – Trends, Policies and Industry Conditions (by Country)

A. NORTH & SOUTH  AMERICA

1. Canada

2. Mexico

3. United States

4. Brazil

5. Chile

6. Colombia

B. ASIA

1. China

2. Japan

3. Korea

4. Malaysia

5. Taiwan

6. Singapore

7. Thailand

C. INDIA

D. AUSTRALIA & NEW ZEALAND

E. EUROPE

1. European Union

a. Policy Overview

b. NETCORD Foundation

2. France

3. Germany & Austria

4. Italy

5. Netherlands

6. Spain

7. Poland

8. Russian Federation

9. United Kingdom

VII. Cost Analysis: Cord Blood Banking

A. Reasons for Variation in Cord Blood Pricing

1. Companies have Flexibility in the Pricing that they Set

2. Companies have Variables in the Services that they Offer

3. Variable Fee Breakdowns

B. Range of Pricing for U.S. Cord Blood Companies (1-100th percentiles)

1. U.S. Cord Blood Banking Price Range (1-100th%)

2. Lowest U.S. Pricing

3. Highest U.S. Pricing

4. Average U.S. Cord Blood Costs (25-75th percentiles)

5. Median Cost of U.S. Storage (50% percentile)

C. Range of Pricing for Canadian Cord Blood Companies (1-100th percentiles)

1. Canadian Cord Blood Banking Price Range (1-100th%)

2. Lowest Canadian Pricing

3. Highest Canadian. Pricing

4. Average Canadian. Cord Blood Costs (25-75th percentiles)

5. Median Cost of Canadian Storage (50% percentile)

VIII. Comparative Analysis of Quality Variables

A. Technical Variables

1. Vapor-Phase Storage vs. Liquid-Phase Storage

2. Cryo-bags vs. Cryo-vials

3. Pentastarch vs. Hetastarch

4. Computer Controlled vs. Manual Rate Freezing

5. Whole Sample vs. Volume Reduction

6. High-Control vs. Low-Control Aseptic Processing

B. Corporate Variables

1. Corporate Stability

2. Scientific Expertise

PART 2: EXPECTANT PARENTS, SURVEY RESULTS & FINDINGS

I. Survey Overview

A. Survey Population

B. Characterization of Market Survey Respondents

1. Geographic Distribution of Market Survey Respondents

2. Household Income Distribution of Survey Respondents

a. All Respondents

b. U.S. Respondents

3. Respondent Breakdown by Race

4. Respondent Breakdown by Gender

5. Respondent Breakdown by Level of Education

6. Respondent Breakdown by Location (City vs. Suburban vs. Rural)

7. Regional Breakdown of U.S. Respondents

8. Demographic Conclusions

II. Rates of Awareness: Unaware / Minimally Informed / Moderately Informed / Knowledgeable

A. Overall

B. By Gender

C. By Household Income

1. All Respondents

2. U.S. Respondents

D. By Education

E. By Race

F. By Geographic Location

1. Region within U.S.

2. Location (City vs. Suburban vs. Rural)

G. By Number of Existing Children within Family (e.g. Birth Order)

III. Factors Influencing Awareness

A. Personal Exposure: Relative Impact of Family, Co-Workers, Peers

B. Informational Sources: Information Sites, Books Medical Pamphlets, Government Sources

C. Medical Exposure: General Doctors, Ob / Gyn, Midwifes, Nurse, Other

D. Promotional Sources:  Internet Advertisements, Print Advertisements, Radio, TV, Other

IV. Factors Influencing Parental Decision-Making

A. Factors Influencing the Decision Not to Store Cord Blood

1.  Knowledge Level

2.  Price Sensitivity

3.  Safety Concerns

4.  Lack of Access

5.  Misconceptions

B. Factors Influencing the Decision for Private vs. Public Storage of Cord Blood

1. Ethical Beliefs

2. Gender

3. Total Household Income

4. Level of Education (Highest Level Achieved by at Least One Parent)

5. Race

6. Geographic Location

a. Region within U.S.

b. City vs. Suburban vs. Rural

7.  Access to Reliable Healthcare

8.  Number of Existing Children within Family (Birth Order)

9.  Source of Knowledge

10. Perceived Support of Medical Staff

11. Family Medical History

C. International Analysis of Cord Blood Banking Perceptions (Region-by-Region)

V. Parental Responsiveness to Health Statistics

A.  Overview

B.  Health Statistics

C.  Health Statistic Conclusions

VI. Parental Expectations

A. Quality of Services

B. Willingness to Educate/Inform

C. Reputability of Organization

VII. Trends

A. Rates of Cord Blood Storage (units per year)

B. Rates of Parental Awareness

C. Cord Blood Research Publication Rates

D. Cord Blood Research Funding Levels

E. Cord Blood Patent Breakdown

F.  Rates of Cord Blood Research Product Development

VIII. Informative Websites: Online Sources Utilized by Expectant Parents

A. Overview of Websites

1. Information Only

2. Commercial Affiliation

B. Dominant Regional Websites (International Analysis)

C. Most Important Criteria Used to Identify Sites to Inform Decision-Making

D. Underlying Reasons for Visiting Online Resources

IX. Conclusions

A. Traits of a “Model Customer”

1. “Model Customer” for a Private Cord Blood Bank

2. “Model Customer” for a Public Cord Blood Bank

B. Ideal Price Range

C. Approaches for Communicating with Expectant Parents

For more information kindly visit
http://www.bharatbook.com/Market-Research-Reports/Choices-in-Cord-Blood-Banking-Factors-Influencing-Parental-Decision-Making.html

Human embryonic stem cells (hESCs) are stem cells derived from the inner cell mass of a blastocyst, which is a stage reach 4-5 days post fertilization. hESCs are the most pluripotent of all stem cell types and can develop into over 200 different cell types of the human body.

hESCs were first derived from mouse embryos in 1981 by Martin Evans and Matthew Kaufman, and independently by Gail R. Martin. In 1995, the first successful culturing of embryonic stem cells from non-human primates occurred at the University of Wisconsin-Madison. Another breakthrough followed at the University of Wisconsin-Madison in November 1998 when a group led by Dr. James Thomson developed a technique to isolate and grow hESCs derived from human blastocysts. Federal funds to support hESC research became available on August 9, 2001, when President Bush announced his decision regarding federal funding for hESC research.

Because of their plasticity and unlimited capacity for self-renewal, hESCs have been proposed for use in wide range of applications, including toxicology testing, tissue engineering, cellular therapies, and basic stem cell biology research. Of particular interest to the medical community is the potential for use of hESCs to heal tissues with naturally limited capacity for renewal, such as the human heart, liver and brain.

This market report recognizes that a wide range of products and services are needed to support this active and well-funded research community. Thus, this report provides:

* Discussion of key advances in hESC research
* A breakdown of hESC research applications, including shared priorities and priorities by segment
* hESC patent analysis
* Historical and future growth projections for the hESC market
* Competitive analysis of providers of hESC research tools
* Overview of specialty pharma companies developing hESC therapies
* Overview of toxicology testing legislation impacting use of hESC in toxicology applications
* A breakdown of hESC research product categories
* Suggestions for novel NSC research products, including cells, kits, assays, media and reagents
* Guidance for companies that wish to offer hESCs products
* And more…

Table of Contents:

I. Background

A. Human Embryonic Stem Cells (hESC)
B. Brief History
C. Use in Treatment of Disease
D. Human Embryonic Stem Cell Line Availability

II. Available Stem Cell Lines

A. NIH Registry Approved
B. Sources of Additional Published hESC Lines
C. Sources of Additional Unpublished hESC Lines

III. Applications

A. Basic Stem Cell Biology
B. Cellular Therapies

1. Overview
2. Heart Regeneration
3. Pancreatic Islet Cell Replacement
4. Neural Regeneration

C. Tissue Engineering
D. Toxicology Testing

IV. Application Priorities

A. Overall

1. Cell-Based Therapies: Greatest shared priority across research community

a. Beneficial hESC Characteristics
b. hESC Safety Concerns
c. hESC Characterization in Vitro
d. hESC Characterization in Vivo

2. Toxicology Assessment: Another area of huge potential

a. Overview
b. Commercial Interest

B. By Segment

1. Academic
2. Biotech
3. Pharma

V. Patents

A. Key U.S. Neuronal Stem and Progenitor Cell Patents

B. Additional Key U.S. Patents

1. Geron Corporation
2. Regents of the University of California
3. BresaGen Inc.
4. Regeneron Pharmaceuticals, Inc.
5. Vanderbuilt University

C. Additional Key European Patents

1. ES Cell International PTE Ltd.
2. DNAVEC Research Inc.
3. University of Edinburgh

VI. Historical and Future Growth Projections

A. PubMed Analysis

1. Historical Analysis (Trailing 10 Years)
2. Future Growth Predictions (5-Year Forecasts)
3. Breakdown of ESC Research by Species

B. CRISP Analysis
C. Patent Analysis

1. All Fields
2. Abstract Only

VII. hESC PRODUCT COMPETITORS

A. Cellartis AB

1. Human embryonic stem cell lines
2. Monoclonal Antibodies for hESC Research
3. Differentiated Cell Products
4. Associated hESC products

B. Vitrolife

C. Tataa Biocenter

D. Invitrogen

1. hESC Culture Media & Reagents
2. hESC-qualified Basement Membrane Extract
3. hESC cDNA Libraries
4. hESC Reporter Cells
5. hESC PCR Kits
6. hESC Stem Cell Antibodies
7. hESC Stem Cell Growth Factors

E. Stem Cell Technologies

1. hESC Culture Media & Reagents
2. hESC Primary & Secondary Antibodies

F. BD Biosciences

G. Chemicon

1. hESC Culture Media and Reagents
2. hESC Lines
3. hESC Kits
4. hESC Antibodies

H. R&D Systems

I. SA Biosciences

J. Thermo Scientific

K. Australian Stem Cell Centre

VIII. Specialty Pharmaceutical Companies developing hESC Therapies

A. Geron
B. Novocell
C. Cell Cure Neurosciences Ltd
D. Cell Dynamics International
E. Advanced Cell Technology

IX. Featured Labs (Potential Customers)

A. Academic Labs
B. Private Labs
C. Government Labs
D. International Labs

X. Toxicology Testing Legislation

1. European Union to Ban Animal-Testing for Cosmetic Development in 2009

2. Responses to the European Ban on Animal Testing for Cosmetic Development

a. Overview
b. Skin Irritation
c. Eye Irritation
d. Skin Sensitisation
e. Mutagenicity/Genotoxicity
f. Reproductive Toxicity

3. EU Legislation Regarding Animal-Based Testing for Drug Discovery

XI. Product Development Suggestions

A. Product Categories

1. hESCs
2. hESC Derivative Cells
3. hESC Reporter Cells
4. hESC Antibodies
5. hESC Characterization & PCR Kits
6. hESC Qualified BME
7. hESC cDNA Libraries
8. hESC Growth Factors
9. hESC Media and Culture Reagents

B. Product Ideas & Suggestions

1. Areas of Underdeveloped Competition
2. Mouse ESC Products
3. iPS Cells Products
4. Non-animal-derived Culture Reagents for hESCs
5. Strategic Collaborations
6. Products for generating Pure ESC populations
7. hESC Toxicity Assay Kit

XII. Events of Interest

For more information kindly visit
http://www.bharatbook.com/Market-Research-Reports/Opportunities-in-Human-Embryonic-Stem-Cells-hESCs.html

Choices in Cord Blood Banking Factors Influencing Parental Decision Making

Cord blood banking is increasingly being used to improve and save lives. Stem cells derived from umbilical blood have been used in more than 14,000 transplants worldwide to treat a wide range of blood diseases, genetic and metabolic disorders, immunodeficiencies and various forms of cancer. However, many expectant parents still do not fully understand the significance of cord blood storage. A study published in the Journal of Reproductive Medicine shows that a third of expectant parents are unaware of the option to preserve cord blood. Of the two-thirds who have some knowledge, 74% describe themselves as ¡§minimally informed.¨

Part 1 of this market report used proprietary data-derivation techniques to analyze conditions of the cord blood banking industry. Part 2 of this report used an end-user survey of expectant parents to identify and analyze the factors involved in the decision to privately store, publicly donate, or discard cord blood at birth. More than 1,200 expectation parents throughout the U.S., as well as Canada, Mexico, Europe, Asia, South/Central America, Australia and other regions answered the detailed survey between November 2008 and January 2009.

The report includes:

Sources through which expectant parents learn of cord blood banking
Rates of parental awareness of cord blood banking by gender, household income, geographic location, education, birth order, and other critical factors
Reasons parents cite as driving the decision to store cord blood
Factors influencing the decision for private vs. public storage of cord blood
Price sensitivity and quality expectations
Comparative analysis of quality variables among cord blood banks and parent perceptions of them
Parental responsiveness to health statistics
Differences in perspective based on global region, as well as differences due to location (city vs. suburban vs. rural)
Critical trends in cord blood banking and the factors influencing them
Competitive analysis of the Cord Blood Banking Industry, including:

U.S. Public Cord Blood Banks
U.S. Private Cord Blood Banks
International Public Cord Blood Banks
International Private Cord Blood Banks

Population Profiling: Characteristics of those highly/moderately/least likely to purchase cord blood banking services
Methods to effectively communicate with your target audience: Expectant Parents
And much more…

Table of Contents:

PART 1: CORD BLOOD BANKING, INDUSTRY OVERVIEW

I. Abstract

II. Cord Blood Stem Cells

A. Fetal Cord Blood Characteristics

B. Existing Treatments

C. Future Applications

III. Cord Blood Banking Industry
A. History
B. Private vs. Public Cord Blood Banks
1. U.S. Public Banks

a. Overview

b. Number of Public Banks

c. Geographic  Distribution

2. U.S. Private Banks
a. Overview

b. Number of U.S. Private Banks

c. Geographic  Distribution

3. Free Programs for U.S. Families with Medical Need

4. International Banks

a. Overview

b. Number Private Cord Blood Banks by International Region

IV. Market Characterization

A. List of U.S.  Private Cord Blood Banks

B. List of U.S. Public Cord Blood Banks

C. U.S. Mail-In Donation Cord Blood Banks

D. Breakdown of Canadian Cord Blood Banks – Public vs. Private / AABB Accredited vs. Non-Accredited

E. International Cord Blood Banks

1. Mexican Cord Blood Banks

a. Private Banks

b. Public Banking System

2. South/Central American Cord Blood Banks

a. Private Banks

b. Public Banking System

3. United Kingdom Cord Blood Banks

a. Private Banks

b. Public Banking System

4. European Cord Blood Banks

a. Private Banks

b. Public Banking System

5. Middle Eastern Cord Blood Banks

a. Private Banks

b. Public Banking System

6. Indian Cord Blood Banks

a. Private Banks

b. Public Banking System

7. Asian Cord Blood Banks

a. Private Banks

b. Public Banking System

8. Australian / New Zealand Cord Blood Banks

a. Private Australian and New Zealand Cord Blood Banks

b. Public Cord Blood Banks by Australian State

i. New South Wales

ii. Victoria

iii. Queensland

iv. Western Austalia, South Australia, & Tasmania

9. African Cord Blood Banks

a. Private Banks

b. Public Banking System

F. List of International Public Cord Blood Banks (Alphabetical by Country)

G. Worldwide List of AABB Accredited Cord Blood Facilities

V. United States Cord Blood Banking Legislation

A. U.S. State

B. U.S. Federal

1. Institute of Medicine Recommendations Study

a. Overview

b. Key Recommendations

c. IOM Study Shapes National Public Health Policy

2. Presidential Executive Order Expanding Approved Stem Cell Lines in Ethically Responsible Ways

a. Background

b. The Order

3. The Stem Cell Therapeutic and Research Act of 2005

a. Background

b. Current Status of the Act

VI. International Analysis – Trends, Policies and Industry Conditions (by Country)

A. NORTH & SOUTH  AMERICA

1. Canada

2. Mexico

3. United States

4. Brazil

5. Chile

6. Colombia

B. ASIA

1. China

2. Japan

3. Korea

4. Malaysia

5. Taiwan

6. Singapore

7. Thailand

C. INDIA

D. AUSTRALIA & NEW ZEALAND

E. EUROPE

1. European Union

a. Policy Overview

b. NETCORD Foundation
2. France

3. Germany & Austria

4. Italy

5. Netherlands

6. Spain

7. Poland

8. Russian Federation

9. United Kingdom

VII. Cost Analysis: Cord Blood Banking

A. Reasons for Variation in Cord Blood Pricing

1. Companies have Flexibility in the Pricing that they Set

2. Companies have Variables in the Services that they Offer

3. Variable Fee Breakdowns

B. Range of Pricing for U.S. Cord Blood Companies (1-100th percentiles)

1. U.S. Cord Blood Banking Price Range (1-100th%)

2. Lowest U.S. Pricing

3. Highest U.S. Pricing

4. Average U.S. Cord Blood Costs (25-75th percentiles)

5. Median Cost of U.S. Storage (50% percentile)

C. Range of Pricing for Canadian Cord Blood Companies (1-100th percentiles)

1. Canadian Cord Blood Banking Price Range (1-100th%)

2. Lowest Canadian Pricing

3. Highest Canadian. Pricing

4. Average Canadian. Cord Blood Costs (25-75th percentiles)

5. Median Cost of Canadian Storage (50% percentile)

VIII. Comparative Analysis of Quality Variables

A. Technical Variables

1. Vapor-Phase Storage vs. Liquid-Phase Storage

2. Cryo-bags vs. Cryo-vials

3. Pentastarch vs. Hetastarch

4. Computer Controlled vs. Manual Rate Freezing

5. Whole Sample vs. Volume Reduction

6. High-Control vs. Low-Control Aseptic Processing

B. Corporate Variables

1. Corporate Stability

2. Scientific Expertise

PART 2: EXPECTANT PARENTS, SURVEY RESULTS & FINDINGS

I. Survey Overview
A. Survey Population

B. Characterization of Market Survey Respondents

1. Geographic Distribution of Market Survey Respondents

2. Household Income Distribution of Survey Respondents

a. All Respondents

b. U.S. Respondents

3. Respondent Breakdown by Race

4. Respondent Breakdown by Gender

5. Respondent Breakdown by Level of Education

6. Respondent Breakdown by Location (City vs. Suburban vs. Rural)

7. Regional Breakdown of U.S. Respondents

8. Demographic Conclusions

II. Rates of Awareness: Unaware / Minimally Informed / Moderately Informed / Knowledgeable

A. Overall

B. By Gender

C. By Household Income

1. All Respondents

2. U.S. Respondents

D. By Education

E. By Race

F. By Geographic Location

1. Region within U.S.

2. Location (City vs. Suburban vs. Rural)

G. By Number of Existing Children within Family (e.g. Birth Order)

III. Factors Influencing Awareness

A. Personal Exposure: Relative Impact of Family, Co-Workers, Peers

B. Informational Sources: Information Sites, Books Medical Pamphlets, Government Sources

C. Medical Exposure: General Doctors, Ob / Gyn, Midwifes, Nurse, Other
D. Promotional Sources:  Internet Advertisements, Print Advertisements, Radio, TV, Other

IV. Factors Influencing Parental Decision-Making

A. Factors Influencing the Decision Not to Store Cord Blood

1.  Knowledge Level

2.  Price Sensitivity

3.  Safety Concerns

4.  Lack of Access

5.  Misconceptions

B. Factors Influencing the Decision for Private vs. Public Storage of Cord Blood

1. Ethical Beliefs

2. Gender

3. Total Household Income

4. Level of Education (Highest Level Achieved by at Least One Parent)

5. Race

6. Geographic Location

a. Region within U.S.

b. City vs. Suburban vs. Rural

7.  Access to Reliable Healthcare

8.  Number of Existing Children within Family (Birth Order)

9.  Source of Knowledge

10. Perceived Support of Medical Staff

11. Family Medical History

C. International Analysis of Cord Blood Banking Perceptions (Region-by-Region)

V. Parental Responsiveness to Health Statistics

A.  Overview

B.  Health Statistics

C.  Health Statistic Conclusions

VI. Parental Expectations

A. Quality of Services

B. Willingness to Educate/Inform

C. Reputability of Organization

VII. Trends

A. Rates of Cord Blood Storage (units per year)

B. Rates of Parental Awareness

C. Cord Blood Research Publication Rates

D. Cord Blood Research Funding Levels

E. Cord Blood Patent Breakdown

F.  Rates of Cord Blood Research Product Development

VIII. Informative Websites: Online Sources Utilized by Expectant Parents

A. Overview of Websites

1. Information Only

2. Commercial Affiliation

B. Dominant Regional Websites (International Analysis)

C. Most Important Criteria Used to Identify Sites to Inform Decision-Making

D. Underlying Reasons for Visiting Online Resources

IX. Conclusions

A. Traits of a “Model Customer”

1. “Model Customer” for a Private Cord Blood Bank

2. “Model Customer” for a Public Cord Blood Bank

B. Ideal Price Range

C. Approaches for Communicating with Expectant Parents

For more please visit
http://www.bharatbook.com/Market-Research-Reports/Choices-in-Cord-Blood-Banking-Factors-Influencing-Parental-Decision-Making.html

Conference on Patient Compliance 2009

Western medicine faces a number of key challenges, not least: an aging population requiring increasing levels of treatment and prescription, spiralling costs of technology and treatment, and growing levels of viral resistance to drugs. Non-compliance is estimated to cost the pharma industry US$70 billion per year. No figures exist for the cost to healthcare insurers and public health but non-compliance is undoubtedly one of the top five issues facing both drug developers and healthcare providers.

For paediatric and geriatric patients, fast-dissolving drug-delivery systems provide an easier way to take medications and vitamins. Oral thin films have evolved to provide systemic delivery of active pharmaceutical ingredients for over-the-counter and soon, prescription drugs.

Visiongain’s Patient Compliance 2009 conference will provide an ideal platform for attendees to discover new partnership and technological possibilities.

By attending this conference you will:
• Discuss the challenges, constraints and opportunities that exist for new value creation
• Be prepared to build lucrative partnerships and take a proactive stance to market opportunities in the area of patient compliance and adherence
• Apply insights on how adherence + persistence = compliance
• Understand the changing demographic nature of the European patient population and evolving patient compliance needs
• Learn about the needs of paediatric and geriatric patient populations and the contribution that can be made through addressing patient compliance
• Implement new technologies that are at the innovative forefront of enhancing patient compliance
• Network with the top decision makers in your industry

Key Speakers
• Dr Philippa Smit-Marshall, Chairman, Institute of Clinical Research’s SIG on Paediatrics
• Tim Davis, CEO, Exco InTouch
• Jeanette Harwood, Research Director, Healthcare Research Worldwide
• Nick Johnson, Business Development Director, IMS Healthcare
• Professor Simon Thom, Professor of Cardiovascular Pharmacology, National Heart and Lung Institute, Imperial College
• Carole North, Director, 90TEN
• Geoff Green, Vice President, Clinical Affairs, Accu-break Pharmaceuticals
• Dr Bernard Vrijens, Chief Scientist, Pharmionic Systems & Adjunct Professor, University of Liège, Belgium, AARDEX Group
• Gareth Morgan, Partner, Taylor Wessing
• Dipti Dashore, Associate, Taylor Wessing
• Assoc. Prof. Przemyslaw Kardas, Head, the First Department of Family Medicine, Medical University of Lodz

Who should attend?
• Branded pharmaceutical companies
• Biotechnology firms
• Medical device firms
• Specialty pharmaceutical firms
• Consultants and solutions providers: working in the areas of: patient compliance, adherence, persistency and disease management.
• University faculties focused on; patient compliance/adherence

Vice-Presidents, CEOs, Directors, Heads and Managers of:
• Patient Relations
• Patient Compliance and Persistency
• Product Management
• Medical Information
• Medical Education
• Clinical Research
• Clinical Project Management
• CRM
• Regulatory Affairs
• Pharmacy Operations
• Strategy Analysis
• Disease Management
• Marketing & Sales

Agenda
Day 1
Day 1, Monday 21st September 2009
09:30 Registration and refreshments
10:00 Opening address from the chair

Dr Philippa Smit-Marshall
Chairman
Institute of Clinical Research’s SIG on Paediatrics

10:10 The scope of patient compliance and its implications
• Why patient compliance matters
• The evolving demographics of patient compliance
• Some facts and figures
• Assessing the opportunity and examining the landscape

Jeanette Harwood
Research Director
Healthcare Research Worldwide

10:50 Co-diagnosis and co-prescription as an untapped opportunity
• What does co-diagnosis and co-prescription actually mean
• Why do they offer an opportunity and what are the implications in practice
• How do these concepts relate to patient compliance?

Nick Johnson
Business Development Director
IMS Healthcare

11:30 Morning refreshments

11:50 The importance of patient compliance to achieving public health goals
• Why patient compliance matters from a public health standpoint
• The evolving demographics of patient compliance
• Why new approaches are needed to address patient compliance
• How the NHS and the private sector can collaborate

12:30 Identifying the barriers to patient compliance
• What are the major barriers for patient compliance at patients, providers and policymakers level?
• The need of a European framework on patient compliance
• How initiatives of industry can be acknowledged in compliance-assuring process

Assoc. Prof. Przemyslaw Kardas
Head, the First Department of Family Medicine
Medical University of Lodz

13:10 Networking lunch

14:10 A geriatric perspective on patient compliance
• The dynamics of the ageing population
• The patient compliance needs of the geriatric population
• The potential contribution of new technologies

Speaker TBC

14:50 A paediatric perspective on patient compliance
• The unique needs of the paediatric market
• The challenges of solving compliance issues for children and young adults
• The potential contributions of new technologies and approaches

Dr Philippa Smit-Marshall
Chairman
Institute of Clinical Research’s SIG on Paediatrics

15:30 Afternoon Refreshments

15:50 The psychology of patient compliance
• Why Patient psychology must be a cornerstone of any attempt to enhance patient compliance
• Using Psychology to formulate a patient-centred approach
• Linking this understanding to an assessment of approaches to enhancing compliance and their limitations

16.30 Panel Discussion Compliance perspectives– A chance for industry to question the experts on evolving trends in patient compliance

17:10 Closing remarks from the chair

17:20 Networking drinks
Take your discussions further and build new relationships in a relaxed and informal setting.

Day 2
Day 2, Tuesday 22nd September 2009
09:30 Registration and refreshments
10:00 Opening address from the chair

Dr Philippa Smit-Marshall
Chairman
Institute of Clinical Research’s SIG on Paediatrics

10:10 Making the most of impending off-patent opportunities
• What happens to a product following API patent expiry
• Understanding the secondary patent and regulatory landscape
• Choosing the right approach from a patent and regulatory perspective
• Maximising the benefits of navigating the patent landscape
• Can product lifecycle management and patient compliance work hand in hand?

Gareth Morgan
Partner
Taylor Wessing

Dipti Dashore
Associate
Taylor Wessing

10:50 The future of the polypill
• Progress on development and the preventative potential
• Constraints on development: The results of the Crestor study and its implications
• The importance of the polypill approach to addressing patient compliance/adherence

Professor Simon Thom
Professor of Cardiovascular Pharmacology,
National Heart and Lung Institute
Imperial College

11:30 Morning refreshments

11:50 Back to Basics – Getting the fundamentals right
• What are the core elements of an effective patient programme
• Deriving insights from both successes and failures
• What really works when it comes to patient compliance

Carole North
Director
90TEN

12.30 Revolutionary tablet technologies for improving patient compliance
• Accu-break tablet systems for unprecedented dose flexibility
• Multiple strengths within a single tablet to facilitate adherence to therapy
• Innovative designs for combination tablets to increase flexibility and compliance

Geoff Green
Vice President, Clinical Affairs
Accu-break Pharmaceuticals

13:10 Networking Lunch

14:10 Electronics for adherence leading to compliance
• Electronic compilation of drug dosing histories in ambulatory patients
• Classifying patients’ drug dosing errors for effective, efficient analysis
• Effective, efficient attainment and maintenance of satisfactory adherence to prescribed drug dosing regimens

Dr Bernard Vrijens
Chief Scientist, Pharmionic Systems & Adjunct Professor,
University of Liège, Belgium
AARDEX Group

14:50 Web 2.0 – The promise and the peril of social media for enhancing patient compliance
• Clearly patients are much more savvy and proactive in terms of seeking information on the internet – how does this impact pharma?
• What is the potential for pharma involvement in social media
• If pharma are to become more involved with social media with respect to patient compliance – how could this be achieved?
• Wherein lies the peril?

Marc Southern
Associate Director, Digital Healthcare
Fleishman-Hillard

15:30 Afternoon refreshments

15:50 Patient compliance and adherence – what can be achieved through the humble mobile phone?
• Use of mobile phones in the world today
- Region
- Demographic
- Therapeutic Area
• Lessons learned from clinical trial case studies
• Results from consumer healthcare campaigns
• Future applications

Tim Davis
CEO
Exco InTouch

16:30 Panel Discussion - Reconciling perspectives: What really works in addressing patient compliance
• The limits of technology and products
• A critical examination of the contribution of psychological insights
• How to find synergy, create value and serve patients

17:10 Chair’s closing remarks

17:15 End of conference

For more information kindly visit
http://www.bharatbook.com/Market-Research-Reports/Conference-on-Patient-Compliance-2009-Conference-only.html

Conference on Patient Compliance 2009
21st - 22nd September 2009, BSG Conference Centre, London, UK

Western medicine faces a number of key challenges, not least: an aging population requiring increasing levels of treatment and prescription, spiralling costs of technology and treatment, and growing levels of viral resistance to drugs. Non-compliance is estimated to cost the pharma industry US$70 billion per year. No figures exist for the cost to healthcare insurers and public health but non-compliance is undoubtedly one of the top five issues facing both drug developers and healthcare providers.

For paediatric and geriatric patients, fast-dissolving drug-delivery systems provide an easier way to take medications and vitamins. Oral thin films have evolved to provide systemic delivery of active pharmaceutical ingredients for over-the-counter and soon, prescription drugs.

Visiongain’s Patient Compliance 2009 conference will provide an ideal platform for attendees to discover new partnership and technological possibilities.

By attending this conference you will:
• Discuss the challenges, constraints and opportunities that exist for new value creation
• Be prepared to build lucrative partnerships and take a proactive stance to market opportunities in the area of patient compliance and adherence
• Apply insights on how adherence + persistence = compliance
• Understand the changing demographic nature of the European patient population and evolving patient compliance needs
• Learn about the needs of paediatric and geriatric patient populations and the contribution that can be made through addressing patient compliance
• Implement new technologies that are at the innovative forefront of enhancing patient compliance
• Network with the top decision makers in your industry

Key Speakers
• Dr Philippa Smit-Marshall, Chairman, Institute of Clinical Research’s SIG on Paediatrics
• Tim Davis, CEO, Exco InTouch
• Jeanette Harwood, Research Director, Healthcare Research Worldwide
• Nick Johnson, Business Development Director, IMS Healthcare
• Professor Simon Thom, Professor of Cardiovascular Pharmacology, National Heart and Lung Institute, Imperial College
• Carole North, Director, 90TEN
• Geoff Green, Vice President, Clinical Affairs, Accu-break Pharmaceuticals
• Dr Bernard Vrijens, Chief Scientist, Pharmionic Systems & Adjunct Professor, University of Liège, Belgium, AARDEX Group
• Gareth Morgan, Partner, Taylor Wessing
• Dipti Dashore, Associate, Taylor Wessing
• Assoc. Prof. Przemyslaw Kardas, Head, the First Department of Family Medicine, Medical University of Lodz

Who should attend?
• Branded pharmaceutical companies
• Biotechnology firms
• Medical device firms
• Specialty pharmaceutical firms
• Consultants and solutions providers: working in the areas of: patient compliance, adherence, persistency and disease management.
• University faculties focused on; patient compliance/adherence

Vice-Presidents, CEOs, Directors, Heads and Managers of:
• Patient Relations
• Patient Compliance and Persistency
• Product Management
• Medical Information
• Medical Education
• Clinical Research
• Clinical Project Management
• CRM
• Regulatory Affairs
• Pharmacy Operations
• Strategy Analysis
• Disease Management
• Marketing & Sales

Agenda
Day 1
Day 1, Monday 21st September 2009
09:30 Registration and refreshments
10:00 Opening address from the chair

Dr Philippa Smit-Marshall
Chairman
Institute of Clinical Research’s SIG on Paediatrics

10:10 The scope of patient compliance and its implications
• Why patient compliance matters
• The evolving demographics of patient compliance
• Some facts and figures
• Assessing the opportunity and examining the landscape

Jeanette Harwood
Research Director
Healthcare Research Worldwide

10:50 Co-diagnosis and co-prescription as an untapped opportunity
• What does co-diagnosis and co-prescription actually mean
• Why do they offer an opportunity and what are the implications in practice
• How do these concepts relate to patient compliance?

Nick Johnson
Business Development Director
IMS Healthcare

11:30 Morning refreshments

11:50 The importance of patient compliance to achieving public health goals
• Why patient compliance matters from a public health standpoint
• The evolving demographics of patient compliance
• Why new approaches are needed to address patient compliance
• How the NHS and the private sector can collaborate

12:30 Identifying the barriers to patient compliance
• What are the major barriers for patient compliance at patients, providers and policymakers level?
• The need of a European framework on patient compliance
• How initiatives of industry can be acknowledged in compliance-assuring process

Assoc. Prof. Przemyslaw Kardas
Head, the First Department of Family Medicine
Medical University of Lodz

13:10 Networking lunch

14:10 A geriatric perspective on patient compliance
• The dynamics of the ageing population
• The patient compliance needs of the geriatric population
• The potential contribution of new technologies

Speaker TBC

14:50 A paediatric perspective on patient compliance
• The unique needs of the paediatric market
• The challenges of solving compliance issues for children and young adults
• The potential contributions of new technologies and approaches

Dr Philippa Smit-Marshall
Chairman
Institute of Clinical Research’s SIG on Paediatrics

15:30 Afternoon Refreshments

15:50 The psychology of patient compliance
• Why Patient psychology must be a cornerstone of any attempt to enhance patient compliance
• Using Psychology to formulate a patient-centred approach
• Linking this understanding to an assessment of approaches to enhancing compliance and their limitations

16.30 Panel Discussion Compliance perspectives– A chance for industry to question the experts on evolving trends in patient compliance

17:10 Closing remarks from the chair

17:20 Networking drinks
Take your discussions further and build new relationships in a relaxed and informal setting.

Day 2
Day 2, Tuesday 22nd September 2009
09:30 Registration and refreshments
10:00 Opening address from the chair

Dr Philippa Smit-Marshall
Chairman
Institute of Clinical Research’s SIG on Paediatrics

10:10 Making the most of impending off-patent opportunities
• What happens to a product following API patent expiry
• Understanding the secondary patent and regulatory landscape
• Choosing the right approach from a patent and regulatory perspective
• Maximising the benefits of navigating the patent landscape
• Can product lifecycle management and patient compliance work hand in hand?

Gareth Morgan
Partner
Taylor Wessing

Dipti Dashore
Associate
Taylor Wessing

10:50 The future of the polypill
• Progress on development and the preventative potential
• Constraints on development: The results of the Crestor study and its implications
• The importance of the polypill approach to addressing patient compliance/adherence

Professor Simon Thom
Professor of Cardiovascular Pharmacology,
National Heart and Lung Institute
Imperial College

11:30 Morning refreshments

11:50 Back to Basics – Getting the fundamentals right
• What are the core elements of an effective patient programme
• Deriving insights from both successes and failures
• What really works when it comes to patient compliance

Carole North
Director
90TEN

12.30 Revolutionary tablet technologies for improving patient compliance
• Accu-break tablet systems for unprecedented dose flexibility
• Multiple strengths within a single tablet to facilitate adherence to therapy
• Innovative designs for combination tablets to increase flexibility and compliance

Geoff Green
Vice President, Clinical Affairs
Accu-break Pharmaceuticals

13:10 Networking Lunch

14:10 Electronics for adherence leading to compliance
• Electronic compilation of drug dosing histories in ambulatory patients
• Classifying patients’ drug dosing errors for effective, efficient analysis
• Effective, efficient attainment and maintenance of satisfactory adherence to prescribed drug dosing regimens

Dr Bernard Vrijens
Chief Scientist, Pharmionic Systems & Adjunct Professor,
University of Liège, Belgium
AARDEX Group

14:50 Web 2.0 – The promise and the peril of social media for enhancing patient compliance
• Clearly patients are much more savvy and proactive in terms of seeking information on the internet – how does this impact pharma?
• What is the potential for pharma involvement in social media
• If pharma are to become more involved with social media with respect to patient compliance – how could this be achieved?
• Wherein lies the peril?

Marc Southern
Associate Director, Digital Healthcare
Fleishman-Hillard

15:30 Afternoon refreshments

15:50 Patient compliance and adherence – what can be achieved through the humble mobile phone?
• Use of mobile phones in the world today
- Region
- Demographic
- Therapeutic Area
• Lessons learned from clinical trial case studies
• Results from consumer healthcare campaigns
• Future applications

Tim Davis
CEO
Exco InTouch

16:30 Panel Discussion - Reconciling perspectives: What really works in addressing patient compliance
• The limits of technology and products
• A critical examination of the contribution of psychological insights
• How to find synergy, create value and serve patients

17:10 Chair’s closing remarks

17:15 End of conference

For more information kindly visit
http://www.bharatbook.com/Market-Research-Reports/Conference-on-Patient-Compliance-2009-Conference-only.html

In 2007, the world market for bone metabolism disorder pharmaceuticals generated sales of over $10bn - how much of this market have you captured?

The majority of this market consists of the fast-expanding osteoporosis segment, a disease with high incidence and under-treatment at present. The bone metabolism market is competitive and progressive, facing generic competition amongst its top-selling drugs. Nevertheless, market growth will be driven by aging populations worldwide and the entry of novel therapies during the years ahead. In Osteoporosis & Bone Metabolism Disorders, 2008-2023, forecasts that the bone metabolism disorder market will increase - but by just how much? Order the report today to find out..

Worldwide, significant numbers of osteoporosis sufferers remain undiagnosed. Amongst those taking medication, patient compliance is poor. In addition, bone metabolism disease patients have significant unmet needs. All these factors provide additional opportunities for further growth in the market. During this growth period, there will be major changes in the nature and make-up of the bone metabolism disorder market. This will include the decline in bisphosphonate drugs and the emergence of novel therapies.

This report reviews the global bone metabolism disorder market in detail thorough comprehensive forecasting and other analysis, as well as interviews with experts in the field, including KOLs in industry. In particular, Osteoporosis & Bone Metabolism Disorders, 2008-2023 concentrates on the following essential aspects of the global osteoporosis and bone metabolism market :

• Financial forecasts covering the period 2008-2023, including leading brands, companies, country markets and therapeutic classes of drug
• Expert opinion from industry sources
• Identification of key drugs in a well-stocked bone metabolism disorder pipeline
• Key industrial players – established and emerging - in the bone metabolism market
• Geographical breakdown of the market, including sales forecasts for leading markets, including China and India

Why you should buy this report :

• To receive a comprehensive analysis of the prospects for the osteoporosis and bone metabolism industry from 2008-2023, including sales forecasts, major growth areas and most talked-about pipeline products
• To discover predicted revenues, growth rates and other key metrics for bone disorder drugs from 2008-2023, especially leading brands
• To determine the forces that influence the osteoporosis and bone metabolism market:
• Drivers and restraints on market
• Competition
• Strengths, weaknesses, opportunities and threats.
• To find out where the bone metabolism market is heading from 2008 onwards - both technologically and commercially

To know more and to buy a copy of your report feel free to visit :  http://www.bharatbook.com/Market-Research-Reports/Osteoporosis-Bone-Metabolism-Disorders-Market-2008-2023-Management-Report-.html

Or

Contact us at:
Bharat Book Bureau
Tel:  +91 22 2757 8668
Fax: +91 22 2757 9131
Email: info@bharatbook.com
Website: www.bharatbook.com
Blog: http://bharatbookresearch.blogspot.com

Investors are turning their attention to antiviral drug discovery because there is a renewed recognition of the promising opportunities in this $20bn market.  Twenty years from the inception of focused antiviral drug research, there are 8 blockbuster drugs currently on the market.  Its double-digit growth makes it a standout segment within the general anti-infective therapeutic class. You should be maximizing your opportunities in this market. The opportunities for success are there now, you should capitalize on them immediately.

The key driver of the market is the rapid development of resistance to existing therapies by the evolving viruses.  The constant need to update the pipeline fuels your investigative and commercial interest in this market – so you must act on this today.  This report - Global Antivirals Market, 2008-2023 - analyses the global antiviral market comprehensively, outlining where you should aim your future developments to guarantee success.  The analyses tackle different aspects of the market, including the leading therapeutic classes, leading antiviral products, key industrial players as partners and financial prospects and opportunities.  The report also delivers in-depth predictions concerning how the market will develop from present until 2023.

Global Antivirals Market, 2008-2023 examines the market for antivirals critically, through comprehensive primary and secondary research.  In addition to consultation with experts in the industry, this research involved a detailed study of policy documents, industrial reports and relevant news. Essentially, visiongain also applied unique in-house techniques such as our developed financial forecasting, SWOT analyses and qualitative projections which are unavailable elsewhere.  The result is a comprehensive market-focused study with detailed financial analyses and uniquely informed opinion on the future of the antivirals market.

In particular, our new Global Antivirals Market 2008-2023 report concentrates on the following essential aspects of that market:

• Antiviral drugs assessment and opportunities

• Key industrial players in the global antivirals market

• Forecasts of global antivirals market from 2008-2023, including in-house developed forecasts of the leading therapeutic agents

• Forecasts for the antiviral therapies in the seven leading developed pharmaceutical country markets and two leading developing markets

• Drivers and opportunities in the global antivirals market

• Restraints and threats in the global antivirals market

• Key opinion from relevant experts - full interview transcripts are included with the report (unavailable anywhere else)

• Coverage of pipeline developments in the antivirals market, with discussion of trends from the present onwards

Why you should buy this report:

• To receive a comprehensive analysis of the prospects for the antivirals industry from 2008-2023, including sales forecasts, major growth areas and most exciting pipeline developments

• To discover predicted revenues, growth rates and other key metrics in the global antivirals market from 2008-2023, with leading brands and principal market segments covered

• To determine the forces that influence the global antivirals market:

• Drivers and restraints on that market

• Competition

• Strengths, weaknesses, opportunities and threats.

• To find out where the global antivirals market is heading from 2008 onwards - both technologically and commercially

The information contained in this report is not available in any other source and is essential reading for you and your colleagues. By ordering and reading this report you can gain market advantage on your competitors today. When aligned with your in-house findings we are confident you will continue to succeed over the next 15 years.

To know more and to buy a copy of your report feel free to visit :  http://www.bharatbook.com/Market-Research-Reports/Global-Antivirals-Market-Analysis-Forecasts-2008-2023.html

Or

Contact us at:
Bharat Book Bureau
Tel:  +91 22 2757 8668
Fax: +91 22 2757 9131
Email: info@bharatbook.com
Website: www.bharatbook.com
Blog: http://bharatbookresearch.blogspot.com

It predicts that there is great potential for the women’s reproductive disorders therapeutics market from present onwards, as this new report Women’s Reproductive Disorders Therapeutics, 2008-2018 shows.

Oral Contraceptive Market
The systemic hormonal contraceptive market is currently a $7bn market, with hormonal oral contraceptives dominating the market for many years. The oral pills are increasingly facing competition from other routes of delivery. With patent expiration, several companies have begun manufacturing generic products. Hormonal contraceptives for women have become the benchmark for the safety and effectiveness of birth control methods.

Although hormonal contraceptives are already a very mature market,  believes that there is still room for further growth. In addition, modern basic research has identified some completely new approaches for the contraceptives of the future. Hormonal oral contraceptives will continue to play an important role in birth control from 2008 to 2018.

Lifecycle Management and Product Line Extension
The hormonal oral contraceptive market is undergoing both lifecycle management and product line extension of existing products in the market. There are progestin-only preparations and combined preparations containing an oestrogen and a progestin. Bayer Schering is developing a pill containing various forms of progestin. Clinical studies show that the new drospirenone pill has an apparent therapeutic effect on premenstrual dysphoria - a particularly severe form of the premenstrual syndrome (PMS), as well as on acne. Pills are increasingly being developed with reduced oestrogen dosages. Evaluates the prospects for extended or continuous administration of oral contraceptives. It is becoming popular for the treatment of endometriosis, dysmenorrhoea and menstrual-associated symptoms.

Menopause and Hormone Replacement Therapy
HRT has been the subject of considerable discussion recently. In light of recent and current studies, provides comprehensive market information on HRT market prospects from 2008 to 2018.

Women’s Reproductive Disorders Therapeutics, 2008-2018 examines that market critically, through comprehensive primary and secondary research. In addition to consultation with industry opinion, this research involved a detailed study of policy documents, industrial reports and relevant news. Importantly, also applied techniques such as financial forecasting, SWOT analyses and qualitative projections. The result is a comprehensive market-based study with detailed financial analyses and informed opinion on the future of the women’s reproductive health market.

In particular, our new Women’s Reproductive Disorders Therapeutics, 2008-2018 report concentrates on the following essential aspects of that market:

• Overview of the women’s reproductive therapies market

• Key industrial players in the global women’s reproductive therapies market

• Forecasts of global market from 2008-2018, including forecasts of the leading therapeutic agents in this market area

• Forecasts for therapies in the seven leading pharmaceutical markets

• Drivers and opportunities in the global women’s reproductive therapies market

• Restraints and threats in the global women’s reproductive therapies market

• Primary research, with full interview transcripts

• Coverage of pipeline developments, with discussion of trends from the present onwards

Why You Should Buy This Report
In Women’s Reproductive Disorders Therapeutics, 2008-2018 you will receive the following essential information for understanding the women’s reproductive disorders therapeutics market and industry:

• The value of the women’s reproductive disorders therapeutics market and its principal market segments from 2008 to 2018

• Which current or future therapies that will drive the market for women’s reproductive disorders therapeutics from 2008 to 2018, with detailed sales forecasts

• Market drivers and restraints, including a comprehensive SWOT analysis for women’s reproductive disorders therapeutics

• The companies involved in the market and their business strategies

This Report would be Useful to the Following Professionals, Amongst Others:

• Business managers of pharmaceutical industry related to women’s reproductive disorders therapeutics

• Researchers, analysts and academics interested in women’s reproductive disorders therapeutics

• Senior staff in healthcare authorities relevant to women’s reproductive disorders therapeutics

• Investors in the pharmaceutical industry relevant to women’s reproductive disorders therapeutics

• Other interested business managers of multinational companies relevant to women’s reproductive disorders therapeutics

• Other business managers of domestic companies

• Academics, researchers and media

To know more and to buy a copy of your report feel free to visit :  http://www.bharatbook.com/Market-Research-Reports/Womens-Reproductive-Disorders-Therapeutics.html

Or

Contact us at:
Bharat Book Bureau
Tel:  +91 22 2757 8668
Fax: +91 22 2757 9131
Email: info@bharatbook.com
Website: www.bharatbook.com
Blog: http://bharatbookresearch.blogspot.com